<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001903'>Anemia</z:hpo>, a decreased oxygen-carrying capacity of the blood, develops frequently in patients with <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Given the wide variation in clinical response to erythropoietin in the treatment of <z:hpo ids='HP_0001903'>anemia</z:hpo> associated with these diseases, 2 meta-analyses of its effectiveness were undertaken </plain></SENT>
<SENT sid="2" pm="."><plain>Databases (MEDLINE and International Pharmaceutical Abstracts) were searched to identify relevant articles </plain></SENT>
<SENT sid="3" pm="."><plain>Search terms included erythropoietin, <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Searches were limited to human subjects and the English language </plain></SENT>
<SENT sid="5" pm="."><plain>Reference lists of identified articles were reviewed for further articles of interest </plain></SENT>
<SENT sid="6" pm="."><plain>The primary author (W.A.M.) selected the articles, and 2 researchers, working independently, extracted the necessary data </plain></SENT>
<SENT sid="7" pm="."><plain>Articles had to meet the following criteria to be included in the meta-analyses: (1) Articles must have dealt with treatment of subjects with documented <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>(2) Studies must have been original research with sample size &gt; or =10 </plain></SENT>
<SENT sid="9" pm="."><plain>(3) Abstracts could be included if the full research manuscript was unavailable </plain></SENT>
<SENT sid="10" pm="."><plain>(4) Patients could not be concurrently receiving other growth factors </plain></SENT>
<SENT sid="11" pm="."><plain>(5) The quality of the selected articles must have been assessed by 2 independent researchers </plain></SENT>
<SENT sid="12" pm="."><plain>A clinical response to erythropoietin was defined as a 0.06 increase in hematocrit or a 20 g/L increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Thirty-nine of the 76 identified articles were included in the meta-analyses </plain></SENT>
<SENT sid="14" pm="."><plain>The effectiveness of erythropoietin was calculated at 87% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, 79% for <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, 40% for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and 13% for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Both subgroup and sensitivity analyses were performed </plain></SENT>
</text></document>